Bio-Imaging Technologies and Phoenix Data Systems to Exhibit at Drug Information Association's (DIA) 44th Annual Meeting.

Meeting to be Held in Boston, Massachusetts, June 22-24

NEWTOWN, Pa. -- Bio-Imaging Technologies, Inc. ("Bio-Imaging") (NASDAQ: BITI) today announced that it will co-exhibit with recently acquired Phoenix Data Systems at the Drug Information Association's [DIA] 44th Annual Meeting to be held June 22-25, 2008 in Boston, Massachusetts.

Bio-Imaging Technologies and Phoenix Data Systems will occupy booth #1444 at the Boston Convention and Exhibition Center. Phoenix Data Systems will showcase its electronic data capture (EDC), interactive voice response (IVR), and data management solutions for improved clinical trials. Bio-Imaging will feature the industry's foremost solutions for medical image management in clinical trials. This unique combination offers an unmatched array of resources, capabilities, and experienced professionals to help maximize the statistical power of clinical data, to better meet timelines and budget, and to obtain regulatory approval.

The exhibition hall will be open Sunday, June 22 from 4-6 pm; Monday, June 23 from 10 am to 6pm; Tuesday, June 24 from 9 am to 5:30 pm; and Wednesday, June 25 from 9 am to 2:30 pm. For additional DIA Annual Meeting information and session details, visit: http://www.diahome.org/DIAHome/FlagshipMeetings/home.aspx?meetingid=14 235. (Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.)

About the Drug Information Association [DIA]

The Drug Information Association serves more than 30,000 professionals in the biotechnology, pharmaceutical and regulatory industries worldwide. Through its domestic and international meetings, training courses, workshops and webinars, DIA provides a neutral global forum for the exchange of information critical to the advancement of the drug discovery and lifecycle management processes. For more information, visit www.diahome.org.

Bio-Imaging Technologies, Inc. is a healthcare contract service organization providing services that support the product development process of the pharmaceutical, biotechnology and medical device industries. The Company has specialized in assisting its clients in the design and management of the medical-imaging component of clinical trials since 1990. Bio-Imaging serves its clients on a global basis through its Core Labs in Newtown, PA, and Leiden, The Netherlands, along with business offices in the United States, The Netherlands, Germany and France. Phoenix Data Systems, Inc., a subsidiary of Bio-Imaging Technologies, is a leading global clinical data services provider of electronic data capture (EDC) services and a comprehensive array of broadly interoperable eClinical data solutions to the pharmaceutical and biotechnology industries. Phoenix Data Systems delivers full service EDC, a unique combination of electronic data capture, interactive voice response, reporting, and data management solutions. Through its CapMed Personal Health Management Suite, Bio-Imaging provides its Personal HealthKey[TM] technology, the Personal Health Record (PHR) software, and CapMed Patient Portal allowing patients to better monitor and manage their health care information. Additional information about Bio-Imaging is available at www.bioimaging.com.

Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company's financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company's filings, especially risk factors contained in the Form 10-K and the recent form 10-Q.